Clinical diagnosis primarily relies on a combination of detecting MDA5 antibodies (with variable sensitivity depending on the detection methods) and IIM classification criteria for dermatomyositis or of the 2018 European Neuromuscular Centre (ENMC). This evidence concerns the gene IFIH1 and dermatomyositis.